The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.

导出 OA

翻译打印收藏纠错

第一作者： Karthik,Nath

第一单位： Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

作者： Karthik,Nath ^[1] ; Sham,Mailankody ^[2] ; Saad Z,Usmani ^[3]

作者单位： Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[1] Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. ^[2] Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: usmanis@mskcc.org. ^[3]

关键词 Bispecific antibodies CAR T-cell therapy Immunotherapeutic agents Multiple myeloma

主题词人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);抗体, 双特异性(Antibodies, Bispecific);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);多发性骨髓瘤(Multiple Myeloma);血液肿瘤(Hematologic Neoplasms)

DOI 10.1016/j.hoc.2023.05.011

PMID 37330347

发布时间 2024-12-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交